Savara Business Summary

Savara Inc. (SVRA) is a clinical-stage biopharmaceutical firm dedicated to the development and commercialization of novel therapies for rare respiratory diseases, specifically autoimmune pulmonary alveolar proteinosis (aPAP). The company’s revenue model is predicated on the high-value commercialization of its lead biologic, MOLBREEVI (molgramostim), which as of February 2026 is under FDA Priority Review following a successful BLA resubmission, with a PDUFA action date of August 22, 2026. Savara operates within the orphan drug segment, targeting a market currently devoid of FDA-approved pharmacological treatments and reliant on invasive whole lung lavage (WLL) procedures; the company has already secured PantheRx Rare Pharmacy as its specialty distribution partner. In the competitive landscape of rare pulmonary medicine, Savara is positioned as a potential first-to-market leader for aPAP, contending with broader respiratory specialists such as Insmed, United Therapeutics, and Verona Pharma for institutional capital and specialized clinical infrastructure. Founded by Rob Neville and Taneli Jouhikainen, Savara is currently led by Chair and CEO Matt Pauls, a veteran executive with a pedigree in rare disease commercialization from his tenures as CEO of Strongbridge Biopharma and Chief Commercial Officer at Insmed. The leadership suite includes Chief Operating Officer Rob Lutz, Chief Financial and Administrative Officer Dave Lowrance, and Chief Commercial Officer Brian Parker, alongside Chief Business and Corporate Affairs Officer Erickson, appointed in February 2026. Savara is backed by a sophisticated roster of institutional investors, including New Enterprise Associates (NEA), Bain Capital Life Sciences, Deerfield Management, and TCG Crossover. This leadership group, supported by a board with deep roots in pulmonary medicine, is focused on leveraging the recent FDA Priority Review of MOLBREEVI to establish a dominant footprint in the orphan respiratory market.